Renaissance Technologies (RenTech)'s MNOV Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 196,800 shares of MediciNova, Inc. (MNOV) worth $257,808, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 39 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in MNOV, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2020, adding 208,400 shares. Largest reduction occurred in Q2 2016, reducing 65,600 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s MediciNova (MNOV) Holding Value Over Time
Track share changes against reported price movement
Quarterly MediciNova (MNOV) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +4,300 | Add 2.23% | 196,800 | $1.31 |
| Q3 2025 | +13,800 | Add 7.72% | 192,500 | $1.27 |
| Q2 2025 | -3,000 | Reduce 1.65% | 178,700 | $1.31 |
| Q1 2025 | +400 | Add 0.22% | 181,700 | $1.46 |
| Q4 2024 | -5,300 | Reduce 2.84% | 181,300 | $2.10 |
| Q3 2024 | -23,400 | Reduce 11.14% | 186,600 | $2.10 |
| Q2 2024 | -20,400 | Reduce 8.85% | 210,000 | $1.44 |
| Q1 2024 | +56,300 | Add 32.34% | 230,400 | $1.45 |
| Q4 2023 | +24,500 | Add 16.38% | 174,100 | $1.50 |
| Q3 2023 | +2,700 | Add 1.84% | 149,600 | $2.09 |
| Q2 2023 | +2,500 | Add 1.73% | 146,900 | $0.00 |
| Q1 2023 | +2,100 | Add 1.48% | 144,400 | $0.00 |
| Q4 2022 | -7,500 | Reduce 5.01% | 142,300 | $0.00 |
| Q3 2022 | -11,300 | Reduce 7.01% | 149,800 | $2.17 |
| Q2 2022 | +11,400 | Add 7.62% | 161,100 | $2.53 |
| Q1 2022 | +7,400 | Add 5.20% | 149,700 | $2.67 |
| Q4 2021 | +13,300 | Add 10.31% | 142,300 | $2.68 |
| Q3 2021 | -6,100 | Reduce 4.52% | 129,000 | $3.79 |
| Q2 2021 | -22,100 | Reduce 14.06% | 135,100 | $4.25 |
| Q1 2021 | -47,100 | Reduce 23.05% | 157,200 | $5.05 |
| Q4 2020 | -5,500 | Reduce 2.62% | 204,300 | $5.26 |
| Q3 2020 | -13,883 | Reduce 6.21% | 209,800 | $5.24 |
| Q2 2020 | -21,217 | Reduce 8.66% | 223,683 | $5.42 |
| Q1 2020 | +208,400 | Add 570.96% | 244,900 | $3.72 |
| Q4 2019 | +36,500 | New Buy | 36,500 | $6.74 |
| Q2 2018 | -65,200 | Sold Out | 0 | $0.00 |
| Q1 2018 | -14,300 | Reduce 17.99% | 65,200 | $10.21 |
| Q4 2017 | +43,900 | Add 123.31% | 79,500 | $6.47 |
| Q3 2017 | +24,600 | Add 223.64% | 35,600 | $6.38 |
| Q2 2017 | +11,000 | New Buy | 11,000 | $5.27 |
| Q3 2016 | -34,500 | Sold Out | 0 | $0.00 |
| Q2 2016 | -65,600 | Reduce 65.53% | 34,500 | $7.54 |
| Q1 2016 | +1,900 | Add 1.93% | 100,100 | $7.34 |
| Q4 2015 | -4,900 | Reduce 4.75% | 98,200 | $3.55 |
| Q3 2015 | -12,600 | Reduce 10.89% | 103,100 | $2.81 |
| Q2 2015 | +4,900 | Add 4.42% | 115,700 | $3.95 |
| Q1 2015 | -5,000 | Reduce 4.32% | 110,800 | $3.50 |
| Q4 2014 | +66,400 | Add 134.41% | 115,800 | $3.04 |
| Q3 2014 | +49,400 | New Buy | 49,400 | $3.00 |
Renaissance Technologies (RenTech)'s MediciNova Investment FAQs
Renaissance Technologies (RenTech) first purchased MediciNova, Inc. (MNOV) in Q3 2014, acquiring 49,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held MediciNova, Inc. (MNOV) for 39 quarters since Q3 2014.
Renaissance Technologies (RenTech)'s largest addition to MediciNova, Inc. (MNOV) was in Q1 2020, adding 244,900 shares worth $911,000.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 196,800 shares of MediciNova, Inc. (MNOV), valued at approximately $257,808.
As of the Q4 2025 filing, MediciNova, Inc. (MNOV) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in MediciNova, Inc. (MNOV) was 244,900 shares, as reported at the end of Q1 2020.